Status:
COMPLETED
Fast Titration Of Quetiapine Versus Currently Approved Titration
Lead Sponsor:
AstraZeneca
Conditions:
Psychotic Disorders
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of a more rapid dose titration in acute schizophrenic patients compared to the conventional titration.
Eligibility Criteria
Inclusion
- Signed informed consent, male or female between 18 and 60 years old, having acute exacerbation of their schizophrenia or schizoaffective disorder requiring admission to hospital. Should stay in hospital for at least 7 days.
Exclusion
- Patients treated with Risperdal consta or Clozapine last 28 days, pregnancy or breast-feeding, patients known to be intolerant or unresponsive to quetiapine, known arrhythmia, other serious medical conditions.
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00254813
Start Date
October 1 2004
End Date
September 1 2005
Last Update
January 26 2011
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Arendal, Norway
2
Research Site
Ålesund, Norway
3
Research Site
Klepp stasjon, Norway
4
Research Site
Kristiansand, Norway